Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO

• The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes
• 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention
• Ongoing CAR T persistence was associated with improved event-free survival
• Autolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below)

LONDON, May 31, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces longer-term follow-up and additional data analysis from the pivotal Phase 1b/2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago).